Growth Hormone Secretagogues

Ipamorelin

Also known as NNC 26-0161

PreliminarySubcutaneous injectionNot FDA-approved for any indication. Was placed on FDA's interim Category 2 list of bulk drug substances in compounding, then removed from that list in September 2024; subsequent Pharmacy Compounding Advisory Committee review did not establish a 503A compounding pathway, leaving its compounding status unresolved. Prohibited in sport (WADA, S2). Research/compounded use only.

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that activates the ghrelin receptor (GHS-R1a) on pituitary cells to trigger growth-hormone release. It is noted in the research literature for selectivity, producing a growth-hormone pulse with comparatively little effect on cortisol and prolactin relative to earlier growth hormone-releasing peptides. Because it works through a pathway distinct from GHRH analogs, it has been studied alongside compounds such as CJC-1295. It is not an approved drug.

Studied / used for

Studied for stimulation of pulsatile growth hormone release
Used in research protocols combined with GHRH analogs
Explored for body composition and recovery contexts

Commonly reported side effects

Injection-site reactions
Headache
Flushing
Lightheadedness
Fluid retention

Preliminary. Mostly early or animal studies. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds